| A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis (NCT06602219) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2024-10-25 |
| A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants (NCT06627088) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2024-08-23 |
| A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants (NCT06503679) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2024-07-16 |
| A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants (NCT06345794) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2024-04-03 |
| A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants (NCT06311656) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2024-03-19 |
| A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants (NCT06092931) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2023-10-16 |
| Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants (NCT06045000) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2023-09-14 |
| A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants (NCT05994807) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2023-08-08 |
| A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis (NCT05896527) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2023-05-02 |
| A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis (NCT06808815) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2021-09-22 |